GGrantIndex
Sort

261,768 grants matching gene therapy

XoLacta: An Adjuvant Therapy for treatment of Radiation Side effects during HER2-Positive Breast Cancer Treatment

$1,022,907
Spencer Reid Marsh · Tiny Cargo Company, The · R44 · FY2025 · CA

Molecular and Cellular Mechanisms of Experience-Dependent Cortical Processing

$1,022,875
Kuan Wang · National Institute Of Mental Health · ZIA · FY2013 · MH

Treatment of Acute Coronary Syndromes with Recombinant LCAT Infusion

$1,022,830
Brian Robert Krause · Alphacore Pharma, Llc · R44 · FY2010 · HL

Natural History of Familial Carcinoid Tumor

$1,022,820
Stephen Wank · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2015 · DK

Retinal Gene Therapy

$1,022,735
Peter Colosi · National Eye Institute · ZIA · FY2012 · EY

Neurogenetic Processes in the Fetal Brain

$1,022,669
Pasko Rakic · Yale University · R01 · FY2012 · NS

Discovery and therapeutic targeting non-coding RNAs in T1D- or T2D-associated atherosclerosis

$1,022,611
Mark W Feinberg · Brigham And Women'S Hospital · U01 · FY2024 · DK

Discovery and therapeutic targeting non-coding RNAs in T1D- or T2D-associated atherosclerosis

$1,022,611
Mark W Feinberg · Brigham And Women'S Hospital · U01 · FY2025 · DK

Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate Cancer

$1,022,522
Vidya P Ramamurthy · Isoprene Pharmaceuticals, Inc. · R44 · FY2025 · CA

Molecular Pathogenesis of Neoplasia

$1,022,497
Richard Youle · National Institute Of Neurological Disorders And Stroke · ZIA · FY2017 · NS

Interacting Signaling Pathways that Initiate Squamous Cell Carcinogenesis

$1,022,419
Stuart H. Yuspa · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

A NOVEL NEUROPROTECTIVE THERAPY FOR ALZHEIMER’S DISEASE

$1,022,134
Menachem Abraham · Klogene Therapeutics, Inc. · R44 · FY2016 · AG

Stalled replication fork repair in cancer predisposition and cancertherapy

$1,022,022
Ralph Scully · Beth Israel Deaconess Medical Center · R35 · FY2022 · CA

Preservation of Proteomic Stability and Promotion of Protein Lipidation by HSF1

$1,021,968
Chengkai Dai · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Pathway and GWAS SNPs: Role in SCCHN Risk, Outcome and Treatment Response

$1,021,889
Brenda Diergaarde · University Of Pittsburgh At Pittsburgh · P50 · FY2012 · CA

Novel Small-Molecule Therapies for CF

$1,021,850
Alan S Verkman · University Of California, San Francisco · P30 · FY2016 · DK

Epigenetic & Post-Translational Mechanisms of Macrophage Resistance to Mycobacterium tuberculosis During HIV Co-Infection

$1,021,774
Thomas R Hawn · University Of Washington · R33 · FY2020 · AI

Molecular Therapy Core Center

$1,021,750
University Of North Carolina Chapel Hill · P30 · FY2005 · DK

Elucidating microvascular contributions to cognitive impairment at single-cell resolution

$1,021,590
Andrew Chris Yang · University Of California, San Francisco · R01 · FY2022 · NS

Inhibition of hepatitis C by RNA-based therapeutics

$1,021,558
Brian H. Johnston · Somagenics, Inc. · R44 · FY2007 · AI

Lymphoma Disease Discovery and Definition

$1,021,536
Elaine Jaffe · Division Of Clinical Sciences - Nci · ZIA · FY2019 · CA

A Haplotype Map for Multiple Sclerosis

$1,021,472
Stephen L Hauser · University Of California, San Francisco · R01 · FY2014 · NS

Novel Insights Into Cerebral Ischemic Pathophysiology In Humans

$1,021,461
Lawrence Latour · National Institute Of Neurological Disorders And Stroke · ZIA · FY2025 · NS

Clinical Research on Nonalcoholic Fatty Liver Disease

$1,021,433
Joel Edward Lavine · Columbia University Health Sciences · U01 · FY2011 · DK

Combined cytokine therapy for sustained HIV remission

$1,021,416
Vijayakumar Velu · Emory University · R01 · FY2023 · AI